Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 50 systematic review(s)/meta-analysis(es). ^[1-49]
• For Nail Psoriasis, brodalumab achieved the highest NAPSI improvement (76.9%) at 24 weeks, followed by etanercept (74%) and ixekizumab (70.5%), with adalimumab and ixekizumab showing the highest complete nail resolution rates (NAPSI 0) at 44.6% and 41%, respectively.
• In Rheumatoid Arthritis (RA), etanercept combined with methotrexate (MTX) led to a 71% ACR20 response rate and 39% ACR50 at 24 weeks, compared to 27% and 3% in the MTX plus placebo group; low disease activity (DAS 28) was more prevalent in the etanercept plus MTX group.
• For Psoriatic Arthritis (PA), secukinumab, infliximab, and adalimumab showed the highest ACR50 responses, while etanercept, infliximab, and certolizumab pegol ranked highest in PsARC responses; etanercept and infliximab notably improved ACR20 and PASI75 outcomes in mixed comparisons.
• In Axial Spondyloarthritis (axSpA), etanercept effectively reduced work impairment and overall productivity loss, indicating its impact on minimizing disease burden.
• Etanercept and golimumab were associated with a lower risk of infection compared to other TNF inhibitors, with injection site reactions being the most common adverse effect.
• No significant differences in the risk of serious adverse events (SAEs) were noted between etanercept and placebo for psoriatic arthritis; however, etanercept demonstrated a lower risk of serious infections compared to certolizumab pegol and infliximab.
• Concerns related to tuberculosis and malignancy were identified with etanercept use, though recent data on long-term risks were unavailable.
• In pediatric psoriasis, etanercept exhibited a favorable safety profile, with a low incidence of adverse effects in the population studied.
• In psoriatic arthritis, studies included adults with varying disease severities and treatment histories, showing etanercept's effectiveness in reducing symptoms, improving physical function, and enhancing quality of life compared to placebo and other biologics.
• For juvenile idiopathic arthritis-associated uveitis (JIA-U) in children aged 2 to 18 years, etanercept demonstrated lower effectiveness than adalimumab in achieving treatment success and preventing treatment failure.